vivani

Vivani Medical, Inc. Company Profile

Background

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company specializing in the development of miniature, long-term drug implants aimed at treating chronic diseases. Leveraging its proprietary NanoPortal™ implant technology, Vivani focuses on addressing two significant challenges in chronic disease management: medication non-adherence and tolerability. The company's mission is to enhance patient outcomes by providing steady, long-term medication delivery, thereby improving adherence and reducing the burden of daily or weekly treatments. Vivani's innovative approach positions it as a significant player in the healthcare industry, particularly in the realm of chronic disease management.

Key Strategic Focus

Vivani's strategic focus centers on the development of its NanoPortal™ implant technology, which enables the delivery of medications over extended periods. The company's core objectives include:

• Developing Long-Term Drug Implants: Creating miniature, subdermal implants that provide steady medication delivery for six months or longer.

• Addressing Medication Non-Adherence: Reducing the challenges associated with daily or weekly medication regimens to improve patient adherence.

• Targeting Chronic Diseases: Focusing on conditions such as obesity, type 2 diabetes, and metabolic disorders in animals.

Vivani utilizes advanced technologies, including its NanoPortal™ platform, to develop these implants. The primary markets targeted are patients with chronic conditions who require consistent medication management.

Financials and Funding

As of April 21, 2026, Vivani Medical's stock (NASDAQ: VANI) is trading at $1.51 per share, with a market capitalization of approximately $83.5 million. The company has a negative earnings per share (EPS) ratio of -$0.44, reflecting its current pre-revenue stage. Vivani has engaged in multiple funding rounds to support its research and development efforts. Notably, in January 2026, the company announced the closing of a common stock offering, strengthening its balance sheet and extending its financial runway into the second quarter of 2026. The capital raised is intended to accelerate the development of NPM-139, Vivani's once or twice-yearly GLP-1 (semaglutide) implant for chronic weight management.

Pipeline Development

Vivani's pipeline includes several key candidates:

• NPM-115: A high-dose exenatide implant in clinical development for chronic weight management in obese or overweight individuals.

• NPM-119: An exenatide implant in preclinical development for the treatment of type 2 diabetes.

• NPM-139: A miniature, subdermal GLP-1 implant under development for chronic weight management.

• OKV-119: An exenatide implant for metabolic diseases in cats.

The company is progressing through various stages of clinical trials and product development, with anticipated milestones in the coming years.

Technological Platform and Innovation

Vivani's proprietary NanoPortal™ implant technology is central to its innovation strategy. This platform enables the development of miniature, long-term drug implants that provide steady medication delivery over extended periods. The technology aims to address challenges associated with fluctuating drug levels and improve patient adherence to treatment regimens.

Leadership Team

Vivani's leadership team comprises experienced professionals:

• Adam Mendelsohn, Ph.D.: Co-Founder, Chief Executive Officer, and Director. Dr. Mendelsohn has a background in biopharmaceuticals and has been instrumental in Vivani's strategic direction.

• Truc Le, M.B.A.: Chief Operations Officer. Ms. Le brings expertise in operations management and has played a key role in streamlining Vivani's operational processes.

• Lisa E. Porter, M.D.: Chief Medical Officer. Dr. Porter provides medical oversight and guidance, ensuring that Vivani's clinical programs align with medical standards and patient needs.

• Anthony Edward Baldor: Chief Financial Officer. Mr. Baldor manages Vivani's financial strategies and has been pivotal in securing funding for the company's initiatives.

• Donald Dwyer, M.B.A.: Chief Business Officer and Corporate Secretary. Mr. Dwyer oversees business development and corporate governance, contributing to Vivani's strategic partnerships and compliance.

These leaders collectively drive Vivani's mission to revolutionize chronic disease treatment through innovative implant technologies.

Competitor Profile

Vivani operates in a competitive landscape with several companies developing implantable medical devices and treatments for chronic diseases. Key competitors include:

• Delcath Systems (DCTH): Focuses on targeted chemotherapy treatments for cancer patients.

• Sight Sciences (SGHT): Develops minimally invasive glaucoma surgical devices.

• Carlsmed (CARL): Specializes in personalized spinal implants.

• Semler Scientific (SMLR): Provides medical devices for cardiovascular disease management.

• Profound Medical (PROF): Develops therapeutic systems for prostate cancer treatment.

Vivani differentiates itself by focusing on long-term drug implants for chronic conditions, leveraging its NanoPortal™ technology to address medication adherence challenges.

Strategic Collaborations and Partnerships

Vivani has established strategic collaborations to enhance its research and development capabilities:

• Cortigent: A subsidiary of Vivani, Cortigent develops targeted neurostimulation systems aimed at restoring critical body functions, such as artificial vision and muscle movement during stroke rehabilitation.

These partnerships strengthen Vivani's market position and innovation capacity, expanding its capabilities in both biopharmaceuticals and medical devices.

Operational Insights

Vivani's strategic considerations include:

• Market Position: Vivani holds a unique position in the market by focusing on long-term drug implants for chronic disease management, addressing a significant unmet need in patient adherence.

• Competitive Advantages: The proprietary NanoPortal™ technology and the development of a diverse pipeline of implantable treatments provide Vivani with distinct competitive advantages.

• Strategic Collaborations: Partnerships with entities like Cortigent enhance Vivani's technological capabilities and broaden its product offerings.

Strategic Opportunities and Future Directions

Vivani's strategic roadmap includes:

• Pipeline Expansion: Advancing the development of NPM-139 and other pipeline candidates to address a broader range of chronic diseases.

• Regulatory Approvals: Navigating the regulatory landscape to achieve approvals for its implantable devices, facilitating market entry.

• Market Penetration: Expanding into new markets and patient populations to maximize the impact of its innovative treatments.

Vivani's current strengths, including its proprietary technology and strategic partnerships, position the company to achieve these objectives and drive future growth.